Genmab — Maj 2025
-
Amgen’s TEPEZZA
▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom https://www.businesswire.com/news/home/20250507246547/en/Amgens-TEPEZZA-teprotumumab-Granted-Marketing-Authorisation-as-the-First-Targeted-Treatment-Specifically-for-Adults-With-Moderate-to-severe-Thyroid-Eye-Disease-TED-in-the-United-Kingdom -
Lundbeck will present on the phase II AMULET trial, investigating amlenetug as a potential new treatment option targeting the rare neurological disorder, multiple system atrophy (MSA),
-at the 2025 International MSA Congress in Boston, U.S., May 9-11. https://www.prnewswire.com/news-releases/lundbeck-to-share-pipeline-data-and-key-insights-into-the-progression-of-rare-disease-multiple-system-atrophy-at-international-msa-congress-in-boston-302449751.html -
Ja, lidt trist p.t. - Novo, Genmab og Zealand gør godt nok det meget lidt kønne for porteføljen p.t. - Vi må nok væbne os med en stor portion af tålmodighed
-
De har ifølge deres hjemmeside lige offentliggjort deres Q1 regnskab for 2024..... Jeg har før brokket mig over deres kommunikationsevner, men det her slår alligevel rekorden
-
Highlights
EPKINLY
(epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional indication as a treatment for relapsed or refractory follicular lymphoma (FL)
Rinatabart sesutecan (Rina-S ) continues to show encouraging antitumor activity in patients with advanced ovarian cancer in data presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO)
Tivdak (tisotumab vedotin) approved by the Japan MHLW and by the European C -
as the first and only antibody-drug conjugate (ADC) approved in both Japan and the European Union (EU) for the treatment of recurrent or metastatic cervical cancer after prior therapy
Gen mab r evenue increase d 19% compared to the first quarter of 2024, to $715 million -
Genmab Announces Financial Results for the First Quarter of 2024 https://proinvestor.com/investornyt/1314391/genmab-announces-financial-results-for-the-first-quarter-of-2024
-
Genmab fastholder prognosen trods stærkt første kvartal pænt over konsensus https://proinvestor.com/investornyt/1314418/genmab-fastholder-prognosen-trods-staerkt-forste-kvartal-paent-over-konsensus
-
Genmab/Sydbank: Stærk toplinje og lavere end ventede omkostninger giver flot drift https://proinvestor.com/investornyt/1314431/genmab-sydbank-staerk-toplinje-og-lavere-end-ventede-omkostninger-giver-flot-drift
-
Genmab leverer et stærkt regnskab, som bør løfte aktien over 1.400 kr. på kort sigt. Selskabet er kun marginalt påvirket af told eller geopolitiske udfordringer, hvilket gør køb under 1.300 kr. attraktive for investorer med tillid til pipelinen – især lovende kandidater. Længere sigt kan positive data fra pipelinen drive kursen mod 2.000 kr. eller mere. Eksisterende succesprodukter genererer betydelige indtægter, og selskabets voksende likviditetsbeholdning styrker deres finansielle position,
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind